Research Spotlight: A New Era of Progress Against Pancreatic Cancer
May 27, 2026 - By Anna Berkenblit, MD, MMSc Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit , PanCAN’s Chief Scientific and Medical Officer. Each month, Dr…
Read the full articleYou might also wanna read
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre
Experimental daraxonrasib pill extends survival for advanced pancreatic cancer patients, study finds
An experimental pill helped people with one of the most deadly cancers in the world live longer, researchers reported this weekend.
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM
Results of the earlier phase 1-2 study of 168 patients, published recently 🧪💊
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre

Experimental daraxonrasib pill nearly doubles survival time in advanced pancreatic cancer trial
Those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients.
Lab Study Finds Compound Stops 90% of Pancreatic Cancer Cell Migration
Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, is particularly deadly and hard to treat.
Lab Study Finds Compound Stops 90% of Pancreatic Cancer Cell Migration
Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, is particularly deadly and hard to treat.

Comments
Sign in to join the conversation.
No comments yet. Be the first.